Identification of the plasma proteomic changes of Coronavirus disease 2019 (COVID-19) is essential to understanding the pathophysiology of the disease and developing predictive models and novel therapeutics.  There are no large-scale efforts to study the plasma proteomic alterations due to COVID-19. We obtained high throughput plasma proteomic data using SomaScan 7K for a large cohort of 482 individuals. We recruited 332 COVID-19 patients with positive SARS-CoV-2 test from March 26, 2020 to September 30, 2020 at Barnes Jewish Hospital, St. Louis Children’s Hospital or affiliated Barnes Jewish Hospital testing sites in St. Louis. We obtained the ventilation status and death status from the hospital records. Using plasma samples collected prior to November 2019, we selected 150 controls by matching on sex, race and age. 


The data including phenotype and plasma proteomic data was generated at Washington University in St. Louis.

Additional information about Knight ADRC datasets available through NIAGADS can be found on the Knight ADRC Collection page.

Carlos Cruchaga, Ph.D.
Washington University in St. Louis

This work was supported by grants from the National Institutes of Health (R01AG044546 (CC), P01AG003991(CC, JCM), RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), and R01AG057777 (OH)), and the Chuck Zuckerberg Initiative (CZI).

The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444 (JCM), P01AG03991(JCM), and P01AG026276(JCM). O.H. is an Archer Foundation Research Scientist.

Acknowledgment statement for any data distributed by NIAGADS:

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.

For investigators using Knight ADRC & WU350 data:

Funding: This work was supported by grants from the National Institutes of Health (R01AG044546 (CC), P01AG003991(CC, JCM), RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), and R01AG057777 (OH)), and the Chuck Zuckerberg Initiative (CZI).
The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444 (JCM), P01AG03991(JCM), and P01AG026276(JCM). O.H. is an Archer Foundation Research Scientist.
This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine.
This study utilized samples obtained from the Washington University School of Medicine’s COVID-19 biorepository, which is supported by: the Barnes-Jewish Hospital Foundation; the Siteman Cancer Center grant P30 CA091842 from the National Cancer Institute of the National Institutes of Health; and the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the view of the NIH.

Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer and coronary disease pathways. iScience. 2022.